BioCentury
ARTICLE | Clinical News

Esperion reports Phase III data for hypercholesterolemia candidate

May 4, 2018 4:09 PM UTC

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) met the primary safety endpoint and key secondary efficacy endpoint in the Phase III CLEAR Harmony (1002-040) trial to treat high-risk atherosclerotic cardiovascular disease (ASCVD) patients with hypercholesterolemia, but also reported a higher incidence of fatal adverse events in the active arm compared with placebo.

Esperion reported a rate of fatal adverse events that were unrelated to study treatment of 0.9% in the bempedoic acid arm compared with 0.3% in the placebo arm. The rate of discontinuation due to adverse events was 10.9% in the bempedoic acid arm vs. 7.1% in the placebo arm, and the rate of serious adverse events was similar between treatment arms (14.5% vs. 14%). The company also reported that eight patients in the bempedoic acid arm had liver enzyme elevations that were more than three times the upper limit of normal...

BCIQ Company Profiles

Esperion Therapeutics Inc.

BCIQ Target Profiles

ATP citrate lyase (ACLY)